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Treatment of Leptomeningeal Metastases Evaluated by
Interphase Cytogenet ics
By R.J. van Oostenbrugge, A.H.N. Hopman, J.W. Arends, F.C.S. Ramaekers, and A. Twijnstra
Purpose: Although cytologic examination of CSF is the
primary method for the evaluation of response to therapy
for leptomeningeal metastases (LMMs), the procedure’s
sensitivity decreases throughout the course of protracted
therapy. We studied whether this response could be mon-
itored more accurately through the detection of numerical
chromosomal aberrations by interphase cytogenetics, us-
ing fluorescence in situ hybridization (FISH).
Patients and Methods: Seven patients treated for
LMMs and with a known numerical aberration for chro-
mosome 1 in their pretreatment CSF were included in
this study. Up to 16 consecutive CSF samples were
analyzed by means of the fluorescence in situ hybrid-
ization (FISH) technique for cells with aberrant chromo-
some 1 content. The results of routine cytology and FISH
analyses were compared and were correlated with
each patient’s neurologic status.
Results: Routine cytology detected malignancies in
only 24 of the 76 samples, all of which were classified
as chromosomally abnormal by FISH (except for two
samples that could not be evaluated). Moreover, FISH
demonstrated aneusomic cells in 32 additional sam-
ples, which could therefore be classified as malig-
nant. The FISH results correlated better with patient
neurologic status in that more malignant cells were
detected in the CSF of neurologically deteriorating
patients.
Conclusion: Using FISH in addition to performing
routine cytologic examination of CSF led to a more
accurate evaluation of response to treatment in patients
treated for LMMs.
J Clin Oncol 18:2053-2058. © 2000 by American
Society of Clinical Oncology.
METASTATIC SPREAD to the leptomeninges is esti-mated to occur in up to 8% of patients with systemic
cancer and is characterized by diffuse and often multifocal
infiltration of the leptomeninges.1 Current treatment modal-
ities include the administration of chemotherapeutic agents
into the subarachnoid space.1,2 Evaluation of treatment
response is difficult, despite the fact that several methods
are currently available. Boogerd et al3 found clinical neu-
rologic status to be a good predictor of the response to
therapy; however, neurologic improvement is generally hard to
achieve because of irreversible damage of the nervous tissue
by the tumor. Tumor response is usually assessed by sequential
cytologic examinations of the CSF.2 However, this method
loses much of its sensitivity throughout the course of protracted
therapy, because of a decrease in cell number, cellular changes
(such as cell enlargement, cytoplasmic vacuolization, and
multinucleation), and the presence of reactive ependymal cells
in the CSF.4 Furthermore, Shapiro et al5 reported that malig-
nant meningeal infiltration was detected at autopsy in all
treated patients, even in patients with apparently normal CSF
cytology results before death.
Additional tests, such as immunocytochemistry and bio-
chemical tumor marker assays, are considered to be of no
additional value in evaluating the response to therapy in the
case of leptomeningeal metastases (LMMs) because of their
lack of sensitivity.2 The few exceptions are carcinoembry-
onic antigen tests in the case of LMMs of solid tumors and
the soluble form of CD-27 in the CSF of patients with
leukemic LMMs, which have proved to be sensitive markers
for response to therapy.6,7
The in situ hybridization technique is based on the
targeted detection of numerical or structural chromosomal
aberrations in the interphase nucleus by means of specific
DNA probes.8 The application of this method is therefore
generally referred to as interphase cytogenetics. The useful-
ness of this technique in CSF cytodiagnosis has been
demonstrated, showing that only malignant CSF samples
contained cells with an increased copy number for chromo-
some 1.9 It has already been demonstrated by flow cytomet-
ric studies that DNA aneuploidy is associated with malig-
nancy and that aneuploidy for chromosome 1 is generally a
good indicator of DNA aneuploidy.10,11 Because other
studies have also detected an exclusive increase in the copy
number of chromosome 1 in (pre)malignant lesions and no
aneusomy for chromosome 1 in normal tissue, it is assumed
that cells with an increased copy number truly represent
malignant cells.12,13 An increase in the copy number of
chromosome 1 is usually accompanied by aberrations in
other chromosomes.14,15
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Recent studies have shown that interphase cytogenetics
are more sensitive than routine cytology in detecting resid-
ual tumor cells present in bone marrow and recurrent
bladder cancer in bladder irrigation specimens.16-18 The aim
of the study presented here was to evaluate the diagnostic
value of interphase cytogenetics for the assessment of
persistent malignancy in the CSF during the treatment of
LMMs.
PATIENTS AND METHODS
Seven patients with LMMs of systemic cancer diagnosed by the
cytologic detection of malignant cells in the CSF, and with a known
numerical aberration for chromosome 1 detected by fluorescence in situ
hybridization (FISH) in the cells of the pretreatment CSF, were
included in this study. All patients were being treated intrathecally or
intraventricularly with chemotherapeutic agents according to standard
protocols.2,19 If three consecutive ventricular CSF samples were found
to be cytologically normal, lumbar CSF was examined. Six mL of CSF,
either ventricular or lumbar, was obtained before every consecutive
bolus injection into the subarachnoid space and was used for the
cytologic examination of Giemsa-stained slides and for the FISH
procedure.
To study the possible influence of chemotherapy on the development
of numerical chromosomal aberrations, we evaluated the CSF of three
additional patients who were also being treated for LMMs but who had
shown no aberration for chromosome 1 in their pretreatment CSF tests.
Each patient underwent a neurological examination before every
intrathecal treatment was administered. This clinical neurologic status
could be classified as improving, stable, or deteriorating.
FISH Protocol
After cytocentrifugation of the 70% ethanol-fixed CSF samples onto
poly-L-lysine–coated glass slides, the preparations were proteolytically
pretreated as previously described.9,20 Pepsin from porcine stomach
(2,500 to 3,500 units per mg protein; Sigma Chemical Co, St. Louis,
MO) was applied at a concentration of 100 mg/mL. in 0.01 N HCl for
20 minutes at 37°C. After the pepsin digestion step, the slides were
rinsed for 5 minutes in 0.01 N HCl at room temperature and subse-
quently dehydrated in an acidified ethanol series (70%, 96%, and
100%). After dehydration, the slides were fixed in 1% paraformalde-
hyde in phosphate-buffered saline for 5 minutes at room temperature,
with five subsequent washes in phosphate-buffered saline and five
washes in double-distilled water. Thereafter, the slides were dehydrated
in 70%, 96%, and 100% ethanol. In situ hybridization was essentially
performed as previously described.9,20 The biotinylated, centromeric
probe for chromosome 1 (1q12, pUC 1.77; Cooke and Hindley21 ) was
hybridized to its target DNA in a hybridization buffer containing 60%
formamide, 2 3 standard saline citrate (SSC; 0.15 NaCl, 15 mmol/L Na
citrate; pH 7.0), 10% dextran sulfate, 0.2 mg/mL yeast tRNA, and 0.2
mg/mL herring sperm DNA under a coverslip and denaturated at 70°C
for 3 minutes on a heating plate. Hybridization was performed
overnight in a moist chamber at 37°C. Posthybridization washes
included 0.1 3 SSC at 60°C for 5 minutes, followed by two washes in
4 3 SSC/Tween 0.05% at room temperature for 5 minutes.
The immunocytochemical detection of the biotinylated probe was
achieved with fluorescein isothiocyanate (FITC)–conjugated avidin
(Vector Laboratories, Burlingame, CA) and subsequent amplification
of the signal by incubation with biotinylated goat antiavidin (Vector
Laboratories) and avidin-FITC (Vector Laboratories). The nuclei were
stained with propidium iodide 0.5 mg/mL (PI; Sigma).
Slide Evaluation
We applied the FISH evaluation criteria as described before in that
(a) overlapping nuclei were excluded, (b) nuclear morphology should
be preserved, (c) the nucleus should be PI-positive and exhibit a low
autofluorescent background, and (d) FISH signals should be of homo-
geneous intensity.8
Samples were classified as disomic if all nuclei examined showed
two FISH signals for chromosome 1. Cells with one signal could not be
interpreted as abnormal, because we had previously found that 2% to
17% of the cells in the CSF samples of patients with nonmalignant
neurologic diseases showed only one FISH signal for chromosome 1 as
a result of colocalization.9 Samples were classified as aneusomic if
nuclei with more than two signals were observed. This numerical
aberration was established in the cytologically malignant cells of the
CSF samples before therapy was started, on the basis of the aberrant
number of FISH signals for chromosome 1, if at least 5% of the nuclei
contained this abnormal copy number, as previously described.22 We
could not, however, use this cutoff level for abnormality during
therapy, because of the low numbers of cells in the CSF samples as a
result of this therapy. Instead, the CSF samples were analyzed
independently by two blinded observers (R.J.v.O., A.H.N.H.) to assess
the quality of the FISH signals by applying the criteria described above.
The CSF samples were classified as abnormal if nuclei with the known
numerical chromosomal aberration for chromosome 1 could be de-
tected.
A Leica-DMRBE microscope (Leica Microskopie & Systeme
GmbH, Wetzlar, Germany) equipped with an appropriate filter set for
FITC and PI was used for microscopy.
RESULTS
A total of 76 CSF samples (59 ventricular and 17 lumbar
punctures) were obtained for routine cytologic examination
and for FISH studies from seven patients known to have the
following malignancies: non-Hodgkin’s lymphoma (three
cases), breast cancer (three cases), and a malignancy of
unknown primary (one case). Table 1 provides an overview
of the cytology and FISH results of all samples taken
Table 1. Comparison of Results of Routine Cytology and the FISH
Procedure in 76 CSF Samples of Patients Treated for LMMs
Cytology Result FISH Result for Chromosome 1
Malignant (n 5 24) Aneusomic (malignant) 22
Disomic (normal) —
Not assessable 2
Suspicious (n 5 13) Aneusomic (malignant) 9
Disomic (normal) 2
Not assessable 2
Normal (n 5 31) Aneusomic (malignant) 18
Disomic (normal) 8
Not assessable 5
Not assessable (n 5 8) Aneusomic (malignant) 5
Disomic (normal) —
Not assessable 3
2054 VAN OOSTENBRUGGE ET AL
Copyright © 2000 by the American Society of Clinical Oncology. All rights reserved. 
Downloaded from www.jco.org at UNIVERSITET MAASTRICHT on March 8, 2005 . 
together. By cytology, 24 CSF samples were classified as
malignant, 13 samples as suspicious, and 31 samples as
normal. Eight samples were not assessable by cytology
because of the absence of cells or loss of cytomorphology.
When the FISH technique was used, 54 samples were found
to contain aneusomic cells, which were therefore classified
as malignant. Ten samples contained no aberrant cells,
whereas 12 samples could not be assessed. All the cytolog-
ically malignant samples could be classified as aneusomic
by FISH, except for two preparations that were not assess-
able by FISH because of a heterogeneous fluorescence
signal distribution. FISH thus detected chromosomal aber-
rations in nine cytologically suspicious samples, in 18
cytologically normal samples, and in five cytologically
unassessable samples, resulting in 32 additional diagnoses
of malignancy. All the 26 follow-up samples of the three
patients without the chromosome 1 aneusomy in the pre-
treatment CSF were disomic, with the exception of two
samples that showed sporadic aneusomic cells.
Table 2 lists the cytology and FISH results of the
individual patients and correlates these with each patient’s
neurologic status. A more accurate evaluation of response to
intrathecal treatment was achieved by inclusion of the FISH
results in six of the seven patients, and these results
correlated well with each patient’s neurologic status. Only
in one patient (case no. 3) was no additional information
obtained by the FISH method. In patient no. 6, treatment
was discontinued because of progressive neurologic deteri-
oration, although no malignant cells were detected by
cytology. The FISH procedure detected aneusomic cells in
most of these cytologically normal samples. In patient no. 7,
most of the samples were cytologically suspicious for
malignancy, whereas FISH detected aneusomic cells in all
of these. In four patients (cases no. 1, 2, 4, and 5), malignant
cells were more frequently demonstrated by FISH than by
routine cytology. In these patients, cytology performed on
lumbar CSF demonstrated the presence of malignant cells
despite a persistently cytologically normal ventricular CSF
for five tests, whereas in four of these instances, aneusomic
cells were still detected by FISH in these ventricular CSF
samples.
The FISH results correlated better with the clinical
neurologic status in that aneusomic cells were found more
often in the CSF samples of clinically deteriorating patients
than malignant cells were detected by cytologic examina-
tion (20 v nine samples, respectively). Also, aneusomy was
detected by FISH more frequently than malignant cells were
Table 2. Results of Cytology and FISH in Consecutive CSF Samples of Individual Patients, Combined With Patient Neurologic Statuses
Patient No. and
Primary Tumor Type Parameter
CSF No.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1. Breast cancer Cytology* 1 1 NA 1 NA 2 2 2 6 1 2 2 2 2 2 2
FISH† 1 1 1 1 NA 2 2 2 1 1 2 1 2 1 1 NA
Neurol‡ impr impr impr impr impr impr impr stable stable stable det det det det det det
2. Breast cancer Cytology 1 1 2 NA 6 2 2 2 1 2 2 2 1 6 NA
FISH 1 1 2 NA 1 1 1 NA 1 1 NA 1 NA 1
Neurol stable stable stable stable stable stable stable stable stable stable stable stable stable stable stable
3. Breast cancer Cytology 1 1 1 1 1 1 6 1 NA 1
FISH 1 1 NA 1 1 1 2 1 1 NA
Neurol stable stable stable stable stable stable det det det det
4. NHL Cytology 1 1 1 1 1 NA 2 NA 6 NA
FISH 1 1 1 1 1 1 1 1 2 NA
Neurol det det det det det det det det det det
5. NHL Cytology 6 2 2 2 2 6 1 6 2 2 2 2 2 6 2
FISH 1 1 1 1 1 1 NA 1 1 1 2 2 1 1 NA
Neurol stable stable stable stable stable stable stable stable stable stable det det det det det
6. NHL Cytology 1 1 2 2 2 2
FISH 1 1 1 NA 1 1
Neurol det det det det det det
7. Unknown Cytology 1 6 6 6 6
primary FISH 1 1 1 1 1
Neurol stable stable stable stable stable
Abbreviations: NA, not assessable; neurol, neurologic status; NHL, non-Hodgkin’s lymphoma.
*Cytology results: 1, malignant; 6, suspicious for malignancy; 2, normal CSF; NA, not assessable.
†FISH results: 1, aneusomy; 2, disomy (normal); NA, not assessable.
‡Neurologic status: impr, improving; stable; det, deteriorating.
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found by cytology in the CSF samples during stable disease
(30 v 11 samples, respectively).
DISCUSSION
A major problem in the current treatment of LMM
patients is the inaccurate assessment of tumor response to
treatment. Tumor response is generally assessed by sequen-
tial cytologic screening of CSF, using the detection of
malignant cells as the major criterion.2 However, cytology
of CSF is only moderately sensitive during treatment,
because of a decrease in cell number and changes in cell
morphology. As a result, the correlation between the out-
come of routine cytodiagnosis and treatment response is weak.
Because the evaluation of treatment could not be im-
proved by the application of immunocytochemical proce-
dures or by assays for tumor markers,1,2 we analyzed the
potential value of interphase cytogenetics in the evaluation
of response to treatment in patients with LMMs. We
assessed the chromosome 1 content in cells of sequential
CSF samples obtained during treatment of seven patients
known to have a numerical aberration for chromosome 1 in
cells of the pretreatment CSF. Although the involvement of
chromosome 1 during tumorigenesis is rather nonspecific
and a result of the increased genetic instability characteristic
of solid tumors, it is a good marker for aneuploidy.23,24 This
has been demonstrated, for example, in breast cancer and
bladder cancer.10,14,24 Furthermore, in the case of breast
cancer, a gain of chromosome 1 is believed to precede
invasion.25 Contrary to these solid tumor findings, a gain of
copy number for chromosome 1 is less frequently observed
in hematologic malignancies, although Johansson et al26
found a gain in the copy number of this chromosome in
almost 20% of a series of non-Hodgkin’s lymphoma pa-
tients during lymphoma progression. Furthermore, aneu-
ploidy of chromosome 1 has not been detected in nonma-
lignant suspensions of different origin, so it could be used as
a marker of (pre)malignancy.12,13,15 As for the cells present
in CSF, we have demonstrated earlier that aneusomy was
only present in CSF samples with cytologically malignant
cells and not in nonmalignant CSF samples.9 In that study,
we demonstrated that aneusomy for chromosome 1 could be
detected in 85% of the cytologically malignant CSF samples
of patients with solid tumors and, more specifically, in up to
80% of the breast cancer patients. Furthermore, we found a
gain in the copy number of chromosome 1 in 50% of the
CSF samples of patients with non-Hodgkin’s lymphoma.
Ideally, the primary tumor should be karyotyped to analyze
its specific genetic aberration, which could then be used to
analyze the cells present in the CSF to detect residual
disease during treatment. However, this technique is time-
consuming, making this option unfeasible in a clinical
setting because therapy has to be initiated as soon as
possible after the diagnosis of LMMs has been made.
Instead of karyotyping, the cells in the first cytologically
malignant CSF sample might be screened by interphase
cytogenetics with a panel of probes to find a reliable genetic
marker to evaluate the response to treatment in larger
numbers of patients.
Although aneusomic cells might develop infrequently
during therapy (two of the 26 control samples of treated
patients sporadically contained aneusomic cells), this does
not interfere with the evaluation of the response to therapy
in patients with a known aberration of chromosome 1.
In all, FISH classified 54 samples as aneusomic, which
were therefore regarded as malignant. In only 24 of these 54
samples could malignant cells be detected by means of
routine cytology. The higher sensitivity of the FISH tech-
nique can be explained from its more objective assessment,8
because strict criteria were applied before cells were con-
sidered to be aneusomic, whereas cytology depends more on
a subjective assessment of cytomorphologic features.27
There are several reasons to take the FISH results in these
samples as an indication of the presence of malignancy.
First of all, in all samples with cytologically normal
ventricular CSF but abnormal FISH results, the presence of
malignant cells was demonstrated in the lumbar CSF by
cytodiagnosis. Secondly, clinical deterioration despite nor-
mal CSF cytology but in the presence of aneusomy was seen
in two of the patients.
Thus the FISH results correlated better with the clinical
course. Grossman et al28 stated that no correlation exists
between neurologic status and CSF cytology during treat-
ment. Others, by contrast, found a good correlation between
the CSF cytology results and clinical parameters and rec-
ommended both criteria for response evaluation.5,29 Boog-
erd et al3 found that neurologic status after the first 6 weeks
of treatment was a better predictor than the cytologic
response at that time. Our results demonstrate that the
correlation between cytology and the clinical course is
weak, whereas the FISH results correlate better with the
neurologic status and course of the disease. It was especially
in cases with deteriorating neurologic status that more often
abnormal CSF samples were detected by the FISH proce-
dure than by routine cytology. In cases with stable neuro-
logic disease, clinical status alone is a poor predictor of
response to therapy. Our results demonstrate that taking the
FISH results into account enables one to discriminate
between stable neurologic disease due to response to ther-
apy and apparent stabilization due to severely damaged
neural tissue but without response to therapy.
Besides cytomorphologic examination, monitoring of
response to treatment has been assessed by the use of
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biochemical markers. Only serial measurements of carcino-
embryonic antigen in the CSF has been found to function as
useful marker in monitoring the response to therapy of
LMMs from solid tumors.6 Other markers, such as lactate
dehydrogenase, beta-glucuronidase, and beta-2 microglobu-
lin, could not be recommended as response criteria during
treatment.30 Also, the application of immunocytochemistry
using several monoclonal antibodies to detect malignant
cells in the CSF samples of patients with LMMs of solid
tumors resulted in only a minor increase in diagnostic
accuracy.31 However, by using an enzyme-linked immu-
nosorbent assay, Kersten et al7 demonstrated a higher
sensitivity of serial measurements of the soluble form of
CD27 in the CSF of patients with LMMs of certain
hematologic malignancies, compared with routine cytology.
The question remains whether the FISH results would
have influenced the treatment protocol had they been taken
into account. In two patients with stable neurologic disease
and normal cytology of the ventricular CSF, but with an
aberration detected by FISH and positive cytology of the
lumbar CSF, an alternative drug would have been adminis-
tered if the FISH results had guided the treatment. In
another patient with stable neurologic disease and persis-
tently suspicious cytology, FISH determined aneusomic
cells in all samples, supporting the diagnosis of persistent
LMMs and thus providing an extra argument for changing
the drug being used. Another patient showed clinical dete-
rioration even though lumbar CSF cytology results appar-
ently normalized during therapy. There are currently no
clear guidelines in such cases. Zachariah et al32 stated that
other chemotherapeutic agents must be used whenever the
neurologic status deteriorates despite normal cytology re-
sults. Other authors have used only CSF cytology as a
response parameter19,33 because a deterioration of neuro-
logic symptoms and signs could be the result of ongoing
damage to nervous-system tissue. The FISH procedure now
offers the clinician an extra argument for changing an
ineffective therapy at an earlier stage in the course of
treatment, as illustrated in our patient with consecutive
cytologically normal CSF samples that all, however, con-
tained aneusomic cells detected by FISH.
Furthermore, lumbar punctures could have been avoided
in some patients. Because the sensitivity of CSF cytology
decreases as a result of the decreasing number of cells in the
course of treatment,4 a phenomenon that is especially
obvious in the cytology of the ventricular CSF,34 a reliable
diagnosis can be made if the clearance of malignant cells
from ventricular CSF during treatment is confirmed by
cytologic examination of lumbar CSF.4 Also, we found
malignant cells by lumbar cytology five times in our series
of patients, despite consecutively normal ventricular CSF
cytology in all five. In four of these five, an aberration in
chromosome 1 was still detectable in the ventricular CSF by
the FISH technique.
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